Zepatier: Difference between revisions

From Proteopedia
Jump to navigationJump to search
No edit summary
No edit summary
Line 1: Line 1:
<StructureSection load='5EPY' size='340' side='right' caption='Zepatier: A combination drug composed of Elbasvir and Grazoprevir.' scene=''>
<scene name='74/746120/Grazoprevir/3'>Text To Be Displayed</scene><StructureSection load='5EPY' size='340' side='right' caption='Zepatier: A combination drug composed of Elbasvir and Grazoprevir.' scene=''>




Line 5: Line 5:


Zepatier is a combination drug combating genotypes 1 and 4 of chronic hepatitis C viral (HCV) infections in adults. It is designed for the treatment of individuals with end stage renal disease on dialysis, typically genotype 1 infected patients. The drug is also utilized to treat genotype 4 patients when other methods of treatment prove ineffective <ref>Petrescu, I. O.; Biciusca, V.; Taisescu, C. I.; Alexandru, D. O.; Taisescu, O.; Comanescu, M. V.; Petrescu, F.; Popescu, I. A.; Trasca, D. M.; ForTofoiu, M. C.; Silosi, C. A.; ForTofoiu, M. Histological factors that predict the liver fibrosis in patients with chronic hepatitis C. Rom. J. Morphol. Embryol. 2016, 57, 759-765.</ref>.<scene name='74/746120/Elbasvir_structure3/1'>Elbasvir</scene> inhibits NS5A, a non-enzymatic protein essential for viral replication and assembly of hepatitis C whose exact mechanism of action is unknown. Elbasvir restricts viral production at the early stage of assembly, in turn preventing spread of the virus<ref name="elbasvir">DOI: 10.1002/cmdc.201300343</ref>.  
Zepatier is a combination drug combating genotypes 1 and 4 of chronic hepatitis C viral (HCV) infections in adults. It is designed for the treatment of individuals with end stage renal disease on dialysis, typically genotype 1 infected patients. The drug is also utilized to treat genotype 4 patients when other methods of treatment prove ineffective <ref>Petrescu, I. O.; Biciusca, V.; Taisescu, C. I.; Alexandru, D. O.; Taisescu, O.; Comanescu, M. V.; Petrescu, F.; Popescu, I. A.; Trasca, D. M.; ForTofoiu, M. C.; Silosi, C. A.; ForTofoiu, M. Histological factors that predict the liver fibrosis in patients with chronic hepatitis C. Rom. J. Morphol. Embryol. 2016, 57, 759-765.</ref>.<scene name='74/746120/Elbasvir_structure3/1'>Elbasvir</scene> inhibits NS5A, a non-enzymatic protein essential for viral replication and assembly of hepatitis C whose exact mechanism of action is unknown. Elbasvir restricts viral production at the early stage of assembly, in turn preventing spread of the virus<ref name="elbasvir">DOI: 10.1002/cmdc.201300343</ref>.  
Grazoprevir is a macrocyclic compound that is able to reversibly bind to the protease, NS3/4A, essential for viral replication. It is responsible for cleavage and processing of the HCV polyprotein. It is hypothesized that the protease is utilized to circumvent immune response at the primary stages of infection <ref>DOI: 10.1021/acschembio.5b00647</ref>.
<scene name='74/746120/Grazoprevir/3'>Grazoprevir</scene> is a macrocyclic compound that is able to reversibly bind to the protease, NS3/4A, essential for viral replication. It is responsible for cleavage and processing of the HCV polyprotein. It is hypothesized that the protease is utilized to circumvent immune response at the primary stages of infection <ref>DOI: 10.1021/acschembio.5b00647</ref>.


== Disease in Humans ==
== Disease in Humans ==